These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30010775)

  • 41. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
    Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
    Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
    Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
    van Heek L; Weindler J; Gorniak C; Kaul H; Müller H; Mettler J; Baues C; Fuchs M; Borchmann P; Ferdinandus J; Dietlein M; Voltin CA; Kobe C; Roth KS
    Eur J Haematol; 2023 Dec; 111(6):881-887. PubMed ID: 37644732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnostic value of FDG-PET in the detection of bone marrow involvement in patients with diffuse large B-cell lymphoma].
    Zhang X; Fan W; Lin XP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):832-5. PubMed ID: 19176040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma.
    Perry C; Lerman H; Joffe E; Sarid N; Amit O; Avivi I; Kesler M; Ben-Ezra J; Even-Sapir E; Herishanu Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2910. PubMed ID: 26945387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Artificial intelligence could alert for focal skeleton/bone marrow uptake in Hodgkin's lymphoma patients staged with FDG-PET/CT.
    Sadik M; López-Urdaneta J; Ulén J; Enqvist O; Krupic A; Kumar R; Andersson PO; Trägårdh E
    Sci Rep; 2021 May; 11(1):10382. PubMed ID: 34001922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone marrow involvement in pediatric malignancies: a comparison study of Positron emission tomographycomputed tomography and bone marrow biopsy.
    Tezol Ö; Sağcan F; Özcan PP; Çıtak EÇ
    Turk J Pediatr; 2020; 62(2):182-190. PubMed ID: 32419409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME
    PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
    Jackson AE; Smeltzer JP; Habermann TM; Jones JM; Burnette B; Ristow K; Wiseman GA; Macon WR; Nowakowski GS; Witzig TE
    Am J Hematol; 2014 Sep; 89(9):865-7. PubMed ID: 24823914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
    Kreissl S; Voltin CA; Kaul H; Bühnen I; Mettler J; Pabst T; Eichenauer DA; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P; Kobe C
    Br J Haematol; 2022 Apr; 197(1):e5-e8. PubMed ID: 34929056
    [No Abstract]   [Full Text] [Related]  

  • 52. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
    Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
    Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
    Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
    Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
    Adams HJ; Nievelstein RA; Kwee TC
    Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
    Cortés-Romera M; Sabaté-Llobera A; Mercadal-Vilchez S; Climent-Esteller F; Serrano-Maestro A; Gámez-Cenzano C; González-Barca E
    Clin Nucl Med; 2014 Jan; 39(1):e46-52. PubMed ID: 23640215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.